Format

Send to

Choose Destination
J Biol Chem. 2013 Dec 13;288(50):36168-78. doi: 10.1074/jbc.M113.496984. Epub 2013 Nov 4.

Inhibitory mechanism of an allosteric antibody targeting the glucagon receptor.

Author information

1
From the Departments of Structural Biology.

Abstract

Elevated glucagon levels and increased hepatic glucagon receptor (GCGR) signaling contribute to hyperglycemia in type 2 diabetes. We have identified a monoclonal antibody that inhibits GCGR, a class B G-protein coupled receptor (GPCR), through a unique allosteric mechanism. Receptor inhibition is mediated by the binding of this antibody to two distinct sites that lie outside of the glucagon binding cleft. One site consists of a patch of residues that are surface-exposed on the face of the extracellular domain (ECD) opposite the ligand-binding cleft, whereas the second binding site consists of residues in the αA helix of the ECD. A docking model suggests that the antibody does not occlude the ligand-binding cleft. We solved the crystal structure of GCGR ECD containing a naturally occurring G40S mutation and found a shift in the register of the αA helix that prevents antibody binding. We also found that alterations in the αA helix impact the normal function of GCGR. We present a model for the allosteric inhibition of GCGR by a monoclonal antibody that may form the basis for the development of allosteric modulators for the treatment of diabetes and other class B GPCR-related diseases.

KEYWORDS:

Antibody Engineering; Diabetes; G Protein-coupled Receptors (GPCR); Glucose Metabolism; Structural Biology

PMID:
24189067
PMCID:
PMC3861664
DOI:
10.1074/jbc.M113.496984
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center